Key Highlights
- Borealis Biosciences launched with $150 million in Series A financing from Versant Ventures and Novartis.
- Strategic research collaboration with Novartis includes up to $100 million in funding and potential $750 million in milestones.
- Focus on RNA therapeutics to address unmet needs in kidney diseases, leveraging advancements in patient stratification and RNA chemistry.
Source: Business Wire
Notable Quotes
- “We’ve recognized over the last six years that some of the most validated targets for kidney disease have been out of reach with traditional modalities. Borealis has the potential to address these targets and reach patients most in need.” — Jerel Davis, Ph.D., Managing Director at Versant Ventures
- “Novartis is committed to bringing forward new therapeutic options for patients with kidney diseases.” — Fiona Marshall, Ph.D., President of Biomedical Research at Novartis
SoHC's Take
Borealis Biosciences is positioned to be a significant player in the field of RNA therapeutics for kidney diseases, building on the success of Chinook Therapeutics. The collaboration between Versant Ventures and Novartis exemplifies the strategic alignment of cutting-edge science with industry expertise, setting the stage for Borealis to address unmet medical needs in a domain where traditional treatments have fallen short. With a strong founding team and substantial financial backing, Borealis is poised to make substantial strides in renal medicine, particularly through its innovative RNA-based approaches.
